Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open-label, safety, efficacy, and pharmacokinetic study

G. Young, Lynn Boshkov, J. E. Sullivan, L. J. Raffini, D. S. Cox, D. A. Boyle, H. Kallender, E. A. Tarka, J. Soffer, M. J. Hursting

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: An increasing number of pediatric patients suffer from thrombotic events necessitating anticoagulation therapy including heparins. Some such patients develop heparin-induced thrombocytopenia (HIT) and thus require alternative anticoagulation. As such, studies evaluating the safety, efficacy, and dosing of alternative anticoagulants are required. Procedure: In this multicenter, single arm, open-label study, 18 patients ≤16 years old received argatroban for either a suspicion of or being at risk for HIT, or other conditions requiring nonheparin anticoagulation. Endpoints included thrombosis, thromboembolic complications, and bleeding. Results: Patients (ages, 1.6 weeks to 16 years) received argatroban usually for continuous anticoagulation (n=13) or cardiac catheterization (n=4). One catheterization patient received a 250μg/kg bolus only; 17 patients received argatroban continuous infusion (median (range)) 1.1 (0.3-12)μg/kg/min (of whom four received a bolus) for 3.0 (0.1-13.8) days. In patients without bolus dosing, typically argatroban 1μg/kg/min was initiated, with therapeutic activated partial thromboplastin times (aPTTs) (1.5-3× baseline) achieved within 7hr. Within 30 days, thrombosis occurred in five patients (two during therapy). No one required amputation or died due to thrombosis during therapy. Two patients had major bleeding. Pharmacometric analyses demonstrated the optimal initial argatroban dose to be 0.75μg/kg/min (if normal hepatic function), with dose reduction necessary in hepatic impairment. Conclusions: In pediatric patients requiring nonheparin anticoagulation, argatroban rapidly provides adequate levels of anticoagulation and is generally well tolerated. For continuous anticoagulation, argatroban 0.75μg/kg/min (0.2μg/kg/min in hepatic impairment), adjusted to achieve therapeutic aPTTs, is recommended.

Original languageEnglish (US)
Pages (from-to)1103-1109
Number of pages7
JournalPediatric Blood and Cancer
Volume56
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Pharmacokinetics
Pediatrics
Safety
Therapeutics
Heparin
Thrombosis
Partial Thromboplastin Time
Thrombocytopenia
Liver
argatroban
Hemorrhage
Cardiac Catheterization
Amputation
Catheterization
Anticoagulants

Keywords

  • Argatroban
  • Children
  • Heparin-induced thrombocytopenia
  • Thrombosis

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Young, G., Boshkov, L., Sullivan, J. E., Raffini, L. J., Cox, D. S., Boyle, D. A., ... Hursting, M. J. (2011). Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open-label, safety, efficacy, and pharmacokinetic study. Pediatric Blood and Cancer, 56(7), 1103-1109. https://doi.org/10.1002/pbc.22852

Argatroban therapy in pediatric patients requiring nonheparin anticoagulation : An open-label, safety, efficacy, and pharmacokinetic study. / Young, G.; Boshkov, Lynn; Sullivan, J. E.; Raffini, L. J.; Cox, D. S.; Boyle, D. A.; Kallender, H.; Tarka, E. A.; Soffer, J.; Hursting, M. J.

In: Pediatric Blood and Cancer, Vol. 56, No. 7, 01.07.2011, p. 1103-1109.

Research output: Contribution to journalArticle

Young, G, Boshkov, L, Sullivan, JE, Raffini, LJ, Cox, DS, Boyle, DA, Kallender, H, Tarka, EA, Soffer, J & Hursting, MJ 2011, 'Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open-label, safety, efficacy, and pharmacokinetic study', Pediatric Blood and Cancer, vol. 56, no. 7, pp. 1103-1109. https://doi.org/10.1002/pbc.22852
Young, G. ; Boshkov, Lynn ; Sullivan, J. E. ; Raffini, L. J. ; Cox, D. S. ; Boyle, D. A. ; Kallender, H. ; Tarka, E. A. ; Soffer, J. ; Hursting, M. J. / Argatroban therapy in pediatric patients requiring nonheparin anticoagulation : An open-label, safety, efficacy, and pharmacokinetic study. In: Pediatric Blood and Cancer. 2011 ; Vol. 56, No. 7. pp. 1103-1109.
@article{b295b01162b74f35b5eb9c7d225abe50,
title = "Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open-label, safety, efficacy, and pharmacokinetic study",
abstract = "Background: An increasing number of pediatric patients suffer from thrombotic events necessitating anticoagulation therapy including heparins. Some such patients develop heparin-induced thrombocytopenia (HIT) and thus require alternative anticoagulation. As such, studies evaluating the safety, efficacy, and dosing of alternative anticoagulants are required. Procedure: In this multicenter, single arm, open-label study, 18 patients ≤16 years old received argatroban for either a suspicion of or being at risk for HIT, or other conditions requiring nonheparin anticoagulation. Endpoints included thrombosis, thromboembolic complications, and bleeding. Results: Patients (ages, 1.6 weeks to 16 years) received argatroban usually for continuous anticoagulation (n=13) or cardiac catheterization (n=4). One catheterization patient received a 250μg/kg bolus only; 17 patients received argatroban continuous infusion (median (range)) 1.1 (0.3-12)μg/kg/min (of whom four received a bolus) for 3.0 (0.1-13.8) days. In patients without bolus dosing, typically argatroban 1μg/kg/min was initiated, with therapeutic activated partial thromboplastin times (aPTTs) (1.5-3× baseline) achieved within 7hr. Within 30 days, thrombosis occurred in five patients (two during therapy). No one required amputation or died due to thrombosis during therapy. Two patients had major bleeding. Pharmacometric analyses demonstrated the optimal initial argatroban dose to be 0.75μg/kg/min (if normal hepatic function), with dose reduction necessary in hepatic impairment. Conclusions: In pediatric patients requiring nonheparin anticoagulation, argatroban rapidly provides adequate levels of anticoagulation and is generally well tolerated. For continuous anticoagulation, argatroban 0.75μg/kg/min (0.2μg/kg/min in hepatic impairment), adjusted to achieve therapeutic aPTTs, is recommended.",
keywords = "Argatroban, Children, Heparin-induced thrombocytopenia, Thrombosis",
author = "G. Young and Lynn Boshkov and Sullivan, {J. E.} and Raffini, {L. J.} and Cox, {D. S.} and Boyle, {D. A.} and H. Kallender and Tarka, {E. A.} and J. Soffer and Hursting, {M. J.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1002/pbc.22852",
language = "English (US)",
volume = "56",
pages = "1103--1109",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Argatroban therapy in pediatric patients requiring nonheparin anticoagulation

T2 - An open-label, safety, efficacy, and pharmacokinetic study

AU - Young, G.

AU - Boshkov, Lynn

AU - Sullivan, J. E.

AU - Raffini, L. J.

AU - Cox, D. S.

AU - Boyle, D. A.

AU - Kallender, H.

AU - Tarka, E. A.

AU - Soffer, J.

AU - Hursting, M. J.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background: An increasing number of pediatric patients suffer from thrombotic events necessitating anticoagulation therapy including heparins. Some such patients develop heparin-induced thrombocytopenia (HIT) and thus require alternative anticoagulation. As such, studies evaluating the safety, efficacy, and dosing of alternative anticoagulants are required. Procedure: In this multicenter, single arm, open-label study, 18 patients ≤16 years old received argatroban for either a suspicion of or being at risk for HIT, or other conditions requiring nonheparin anticoagulation. Endpoints included thrombosis, thromboembolic complications, and bleeding. Results: Patients (ages, 1.6 weeks to 16 years) received argatroban usually for continuous anticoagulation (n=13) or cardiac catheterization (n=4). One catheterization patient received a 250μg/kg bolus only; 17 patients received argatroban continuous infusion (median (range)) 1.1 (0.3-12)μg/kg/min (of whom four received a bolus) for 3.0 (0.1-13.8) days. In patients without bolus dosing, typically argatroban 1μg/kg/min was initiated, with therapeutic activated partial thromboplastin times (aPTTs) (1.5-3× baseline) achieved within 7hr. Within 30 days, thrombosis occurred in five patients (two during therapy). No one required amputation or died due to thrombosis during therapy. Two patients had major bleeding. Pharmacometric analyses demonstrated the optimal initial argatroban dose to be 0.75μg/kg/min (if normal hepatic function), with dose reduction necessary in hepatic impairment. Conclusions: In pediatric patients requiring nonheparin anticoagulation, argatroban rapidly provides adequate levels of anticoagulation and is generally well tolerated. For continuous anticoagulation, argatroban 0.75μg/kg/min (0.2μg/kg/min in hepatic impairment), adjusted to achieve therapeutic aPTTs, is recommended.

AB - Background: An increasing number of pediatric patients suffer from thrombotic events necessitating anticoagulation therapy including heparins. Some such patients develop heparin-induced thrombocytopenia (HIT) and thus require alternative anticoagulation. As such, studies evaluating the safety, efficacy, and dosing of alternative anticoagulants are required. Procedure: In this multicenter, single arm, open-label study, 18 patients ≤16 years old received argatroban for either a suspicion of or being at risk for HIT, or other conditions requiring nonheparin anticoagulation. Endpoints included thrombosis, thromboembolic complications, and bleeding. Results: Patients (ages, 1.6 weeks to 16 years) received argatroban usually for continuous anticoagulation (n=13) or cardiac catheterization (n=4). One catheterization patient received a 250μg/kg bolus only; 17 patients received argatroban continuous infusion (median (range)) 1.1 (0.3-12)μg/kg/min (of whom four received a bolus) for 3.0 (0.1-13.8) days. In patients without bolus dosing, typically argatroban 1μg/kg/min was initiated, with therapeutic activated partial thromboplastin times (aPTTs) (1.5-3× baseline) achieved within 7hr. Within 30 days, thrombosis occurred in five patients (two during therapy). No one required amputation or died due to thrombosis during therapy. Two patients had major bleeding. Pharmacometric analyses demonstrated the optimal initial argatroban dose to be 0.75μg/kg/min (if normal hepatic function), with dose reduction necessary in hepatic impairment. Conclusions: In pediatric patients requiring nonheparin anticoagulation, argatroban rapidly provides adequate levels of anticoagulation and is generally well tolerated. For continuous anticoagulation, argatroban 0.75μg/kg/min (0.2μg/kg/min in hepatic impairment), adjusted to achieve therapeutic aPTTs, is recommended.

KW - Argatroban

KW - Children

KW - Heparin-induced thrombocytopenia

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=79151473713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151473713&partnerID=8YFLogxK

U2 - 10.1002/pbc.22852

DO - 10.1002/pbc.22852

M3 - Article

C2 - 21488155

AN - SCOPUS:79151473713

VL - 56

SP - 1103

EP - 1109

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -